Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)
November 18, 2024 11:22 AM ESTTD Cowen analyst Tara Bancroft reiterated a Hold rating on Fate Therapeutics (NASDAQ: FATE).
The analyst commented, "The first SLE patient treated with FT819 (iCAR-T) is now past 6 months with ongoing clinical remission, low disease activity, and resolution of key quality of life... More
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study
November 18, 2024 8:05 AM ESTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. The patient, a 27-year-old African American-Asian woman diagnosed with lupus nephritis (LN) over ten years ago, received fludarabine-free conditioning followed by a single dose of... More
